Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche adds kidney cancer to anti-PD-L1 programme

Roche adds kidney cancer to anti-PD-L1 programme Sales of the company's HER2-targeting drugs - Herceptin (trastuzumab) and follow-up therapies Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - grew 23% thanks to increased use of Herceptin and Perjeta in ... The growth of Perjeta - up 82% to

England's Cancer Drugs Fund: Fixing a broken system

England's Cancer Drugs Fund: Fixing a broken system The Swiss firm has, in relative terms at least, not come out too badly during the de-listing process as two of its newer cancer medicines, namely breast cancer treatments Perjeta

Roche's newer breast cancer drugs gain traction

Roche's newer breast cancer drugs gain traction Perjeta and Kadcyla boost 2014 revenues. Solid growth for Roche's breast cancer blockbuster Herceptin was backed up by big gains for two follow-up products in the last quarter for ... Roche's breast cancer franchise was particularly boosted by the

Pharma condemns Cancer Drugs Fund cuts

Pharma condemns Cancer Drugs Fund cuts Among the more contemplative companies was Roche, which escaped having newer cancer drugs such as Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) removed from the list, although the CDF will no longer

Double trial disappointment for Roche

Double trial disappointment for Roche The regimens were Kadcyla plus Roche's Perjeta (pertuzumab), Kadcyla alone and Herceptin plus taxane chemotherapy.

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics